RAD-140 vs Retatrutide for weight loss
Short answer: For weight loss, users rate them about the same: 92% report improvement with RAD-140 (51 reports) and 91% with Retatrutide (222 reports).
RAD-140 has 0 meta-analyses and 0 randomized trials on PubMed; Retatrutide has 22 and 6.
Based on 684 reports about RAD-140 and 446 about Retatrutide. Not medical advice.
| RAD-140 SARM | Retatrutide Peptide | |
|---|---|---|
| User score | 44 | 71 |
| Verdict | Mixed | Mostly positive |
| Positive of reports that state an outcome | 42% | 76% |
| Reports | 684 | 446 |
| Research | DResearch: None | BResearch: Moderate |
| Meta-analyses / RCTs | 0 / 0 | 22 / 6 |
| Mainly used for | ||
| Weight loss % reporting improvement | 92% (51) | 91% (222) |
| Appetite % reporting improvement | 56% (9) | 73% (84) |
| Focus % reporting improvement | 17% (6) | 83% (6) |
| Energy % reporting improvement | 41% (51) | 69% (75) |
| Sleep % reporting improvement | 3% (39) | 31% (26) |
| Anxiety % reporting improvement | 7% (15) | 40% (5) |
| Mood % reporting improvement | 37% (52) | 66% (32) |
| Memory % reporting improvement | 100% (2) | — |
| Performance % reporting improvement | 93% (296) | 82% (33) |
| Recovery % reporting improvement | 96% (28) | 100% (8) |
| Pain & inflammation % reporting improvement | 17% (12) | 78% (9) |
| Digestion % reporting improvement | 0% (3) | 46% (13) |
| Libido % reporting improvement | 42% (38) | 25% (12) |
| Hormones % reporting improvement | 5% (62) | 100% (13) |
| Blood sugar % reporting improvement | — | 75% (4) |
| Heart & lipids % reporting improvement | 6% (32) | 37% (19) |
| Skin & hair % reporting improvement | 0% (11) | — |
| Common side effects | suppression, hair loss, fatigue, insomnia | nausea, fatigue, stomach issues, insomnia |
| Typical dose reported | Not listed | Not listed |
“I did put on decent size and I feel a lot fuller. My strength and endurance has gone up tremendously. Side effects - Shedding of hair, anxiety...”
This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.
Pharmacol Rev, 2025 ↗“Drastically reduced appetite: At 5mg, I experienced near-total suppression of hunger and cravings. Steady, effortless fat loss: I didn't have to track macros obsessively or do extreme cardio.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate